A vaccine composed of 2.0 each heat shock protein 70- and glypican 3-derived peptide, 1.4 poly-ICLC and 1.0 mg hLAG-3Ig is safe for perioperative immunotherapy in patients with human leukocyte antigen-matched HCC and effectively promotes CD8+ T cell tumor infiltration (89). Here, CD8A is linked to neoplasm.